Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoVax and Pembrolizumab in Newly Diagnosed Glioblastoma
NCT02287428Phase 1Active, not recruiting
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Nov 2014
- Primary completion
- Feb 2027
- Countries
- 1
01
Overview
Phase 1, open-label trial in glioblastoma (GBM) (5 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Number of participants with Adverse Events at 2 years, Number of participants with at least 10 actionable peptides at 2 years and 1 more. Started Nov 2014; status: active, not recruiting.
02
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02287428.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02287428.